NYSE:CO

Stock Analysis Report

Executive Summary

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.

Risks

  • Global Cord Blood has significant price volatility in the past 3 months.
  • Global Cord Blood is not covered by any analysts.

Similar Companies

Share Price & News

How has Global Cord Blood's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.4%

CO

-0.3%

US Healthcare

-0.6%

US Market


1 Year Return

-28.9%

CO

-9.2%

US Healthcare

0.7%

US Market

CO underperformed the Healthcare industry which returned -9.1% over the past year.

CO underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

COIndustryMarket
7 Day3.4%-0.3%-0.6%
30 Day-17.9%2.1%4.9%
90 Day-18.4%-0.8%1.7%
1 Year-28.9%-28.9%-7.8%-9.2%3.0%0.7%
3 Year-14.0%-14.9%29.7%24.4%44.8%35.4%
5 Year-8.3%-9.2%66.1%56.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Global Cord Blood's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Global Cord Blood undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Global Cord Blood's share price is below the future cash flow value, and at a moderate discount (> 20%).

Global Cord Blood's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Global Cord Blood is good value based on earnings compared to the US Healthcare industry average.

Global Cord Blood is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Global Cord Blood, we can't assess if its growth is good value.


Price Based on Value of Assets

Global Cord Blood is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Global Cord Blood expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Global Cord Blood is high growth as no revenue estimate data is available.

Global Cord Blood's earnings are expected to grow by 15% yearly, however this is not considered high growth (20% yearly).

Unable to compare Global Cord Blood's revenue growth to the United States of America market average as no estimate data is available.

Global Cord Blood's earnings growth is expected to exceed the United States of America market average.

Global Cord Blood's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Global Cord Blood will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Global Cord Blood performed over the past 5 years?

27.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Global Cord Blood has delivered over 20% year on year earnings growth in the past 5 years.

Global Cord Blood's 1-year earnings growth exceeds its 5-year average (35% vs 27.7%)

Global Cord Blood's earnings growth has exceeded the US Healthcare industry average in the past year (35% vs 5.6%).


Return on Equity

Global Cord Blood has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Global Cord Blood used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Global Cord Blood has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Global Cord Blood's financial position?


Financial Position Analysis

Global Cord Blood is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Global Cord Blood's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Global Cord Blood has no debt.

Global Cord Blood has no debt compared to 5 years ago when it was 57.5%.

Global Cord Blood has no debt, it does not need to be covered by operating cash flow.

Global Cord Blood has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Global Cord Blood has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Global Cord Blood's current dividend yield, its reliability and sustainability?

1.66%

Current Dividend Yield


Dividend Yield and Payments Analysis

Global Cord Blood's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Global Cord Blood's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

It is too early to tell whether Global Cord Blood has stable dividend payments.

Global Cord Blood only just started paying a dividend, it is too early to tell if payments are increasing.


Current Payout to Shareholders

Dividends paid are well covered by earnings (5.3x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Global Cord Blood's salary, the management and board of directors tenure and is there insider trading?

10.3yrs

Average board tenure


CEO

Tina Zheng (47yo)

0yrs

Tenure

CN¥465,362

Compensation

Ms. Ting Zheng, also known as Tina, serves as the Chief Executive Officer and Chief Executive Officer of Beijing Division of China Cord Blood Corporation and had been its Interim Chief Executive Officer of ...


CEO Compensation Analysis

Tina's remuneration is lower than average for companies of similar size in United States of America.

Tina's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

10.3yrs

Average Tenure

49yo

Average Age

The average tenure for the Global Cord Blood board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Albert Chen (43yo)

    CFO & Director

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Tina Zheng (47yo)

    Chairperson

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Rui Arashiyama (60yo)

    Chief Executive Officer of Guangdong & Zhejiang Divisions

    • Tenure: 0yrs
    • Compensation: CN¥529.88k
  • Xin Xu (65yo)

    Chief Technology Officer

    • Tenure: 0yrs
    • Compensation: CN¥159.34k
  • Cathy Bai

    Vice President of Corporate Finance

    • Tenure: 0yrs

Board Members

  • Mark D. Chen (51yo)

    Independent Non-Executive Director

    • Tenure: 0yrs
  • Ken Lu (57yo)

    Independent Non-Executive Director

    • Tenure: 10.3yrs
  • Jennifer Weng (51yo)

    Independent Non-Executive Director

    • Tenure: 10.3yrs
  • Albert Chen (43yo)

    CFO & Director

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Tina Zheng (47yo)

    Chairperson

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Ping Xu (40yo)

    Non-Executive Director

    • Tenure: 1.7yrs

Company Information

Global Cord Blood Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Cord Blood Corporation
  • Ticker: CO
  • Exchange: NYSE
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$550.626m
  • Shares outstanding: 121.55m
  • Website: https://www.globalcordbloodcorp.com

Number of Employees


Location

  • Global Cord Blood Corporation
  • Bank of China Tower
  • 48th Floor
  • Central
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CONYSE (New York Stock Exchange)YesOrdinary SharesUSUSDJul 2009
6CBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2009

Biography

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, process ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:51
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.